Nature:Jennifer Doudna团队发现新型CRISPR基因组编辑酶

2019-02-10 Nature自然科研 Nature自然科研

《自然》本周发表的一篇论文CasX enzymes comprise a distinct family of RNA-guided genome editors报告了一种能调控人类基因组的新型酶CasX,其编辑功能与先前已描述的CRISPR–Cas系统都不相同,这为CRISPR工具箱再添一员。

《自然》本周发表的一篇论文CasX enzymes comprise a distinct family of RNA-guided genome editors报告了一种能调控人类基因组的新型酶CasX,其编辑功能与先前已描述的CRISPR–Cas系统都不相同,这为CRISPR工具箱再添一员。



CasX能有效地体内操纵基因组

CRISPR–Cas系统在Cas核酸酶家族成员的帮助下进行基因组编辑,这些酶能切割DNA。Cas9与Cas12a为这项技术奠定了基础,但研究人员也在寻找其它的Cas酶。



CasX三元复合物的整体结构

美国加州大学伯克利分校的Jennifer Doudna与同事从地下水的微生物中分离得到了一种此类核酸酶,称其为CasX。CasX的一大重要应用特点在于其比Cas9或Cas12a都要小得多(不到1000个氨基酸)。分析显示,CasX能同时修饰人类和大肠杆菌的基因组。

研究人员指出,CasX编辑DNA的机制与Cas9或Cas12a的机制在功能上存在差异。CasX的结构具有其它Cas蛋白中未曾发现的特征,比如含有一个参与DNA解螺旋的结构域;其反式切割活性似乎也比其它Cas系统要少。

CasX不仅小巧,还具有独特的可编程编辑方式,或具备目前CRISPR–Cas基因组编辑技术所没有的优势。

原始出处:
Jun-Jie Liu, Natalia Orlova, Benjamin L. Oakes, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature. Feb 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933580, encodeId=24a4193358024, content=<a href='/topic/show?id=04cb1354312' target=_blank style='color:#2F92EE;'>#OUD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13543, encryptionId=04cb1354312, topicName=OUD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Fri Apr 05 18:42:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784671, encodeId=8f631e84671fc, content=<a href='/topic/show?id=e9506199cf' target=_blank style='color:#2F92EE;'>#Doudna#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6199, encryptionId=e9506199cf, topicName=Doudna)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Aug 31 12:42:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883589, encodeId=7c2a18835898b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 08 21:42:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276111, encodeId=39ab12e611158, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585962, encodeId=4ef31585962d0, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2a17339944, createdName=维他命, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-04-05 zxxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933580, encodeId=24a4193358024, content=<a href='/topic/show?id=04cb1354312' target=_blank style='color:#2F92EE;'>#OUD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13543, encryptionId=04cb1354312, topicName=OUD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Fri Apr 05 18:42:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784671, encodeId=8f631e84671fc, content=<a href='/topic/show?id=e9506199cf' target=_blank style='color:#2F92EE;'>#Doudna#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6199, encryptionId=e9506199cf, topicName=Doudna)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Aug 31 12:42:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883589, encodeId=7c2a18835898b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 08 21:42:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276111, encodeId=39ab12e611158, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585962, encodeId=4ef31585962d0, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2a17339944, createdName=维他命, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-08-31 xqptu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933580, encodeId=24a4193358024, content=<a href='/topic/show?id=04cb1354312' target=_blank style='color:#2F92EE;'>#OUD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13543, encryptionId=04cb1354312, topicName=OUD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Fri Apr 05 18:42:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784671, encodeId=8f631e84671fc, content=<a href='/topic/show?id=e9506199cf' target=_blank style='color:#2F92EE;'>#Doudna#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6199, encryptionId=e9506199cf, topicName=Doudna)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Aug 31 12:42:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883589, encodeId=7c2a18835898b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 08 21:42:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276111, encodeId=39ab12e611158, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585962, encodeId=4ef31585962d0, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2a17339944, createdName=维他命, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-06-08 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933580, encodeId=24a4193358024, content=<a href='/topic/show?id=04cb1354312' target=_blank style='color:#2F92EE;'>#OUD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13543, encryptionId=04cb1354312, topicName=OUD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Fri Apr 05 18:42:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784671, encodeId=8f631e84671fc, content=<a href='/topic/show?id=e9506199cf' target=_blank style='color:#2F92EE;'>#Doudna#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6199, encryptionId=e9506199cf, topicName=Doudna)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Aug 31 12:42:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883589, encodeId=7c2a18835898b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 08 21:42:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276111, encodeId=39ab12e611158, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585962, encodeId=4ef31585962d0, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2a17339944, createdName=维他命, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-02-12 yuandd
  5. [GetPortalCommentsPageByObjectIdResponse(id=1933580, encodeId=24a4193358024, content=<a href='/topic/show?id=04cb1354312' target=_blank style='color:#2F92EE;'>#OUD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13543, encryptionId=04cb1354312, topicName=OUD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Fri Apr 05 18:42:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784671, encodeId=8f631e84671fc, content=<a href='/topic/show?id=e9506199cf' target=_blank style='color:#2F92EE;'>#Doudna#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6199, encryptionId=e9506199cf, topicName=Doudna)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Aug 31 12:42:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883589, encodeId=7c2a18835898b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 08 21:42:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276111, encodeId=39ab12e611158, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585962, encodeId=4ef31585962d0, content=<a href='/topic/show?id=7ed041850a1' target=_blank style='color:#2F92EE;'>#基因组编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41850, encryptionId=7ed041850a1, topicName=基因组编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2a17339944, createdName=维他命, createdTime=Tue Feb 12 09:42:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]

相关资讯

Science:肥胖可怕?别怕,科学家们找到阻止它的“魔剪”技术

超重(overweight)和肥胖(obesity)一直是个威胁公众健康的大问题。但是,很多人并不想这样,特别是对于因为基因突变而引发肥胖症状的人而言,这很委屈。

基因疗法解题①:格尔辛基之死到CRISPR,失望与希望

基因疗法:失望与希望什么是基因?基因是一段由脱氧核糖核酸(DNA)或核糖核酸(RNA)编码的遗传信息。基因可以表达具有生物学功能的大分子,一般是蛋白质,有时候是RNA。人类基因组有三十亿个碱基对,其中大概只有2%的碱基序列编码基因。科学家估计人体大概有两万个基因。这些基因并不是孤立的模块,而是在基因网络构成的遗传背景之上发挥作用。人们很早就认识到有些疾病是可遗传的。换言之,这些疾病的起因在于基

Cell:突破,升级版CRISPR筛选工具成功改造免疫细胞,并提高其抗癌能力

杀伤性T细胞在免疫介导的癌症、传染病和自身免疫疾病的控制中发挥核心作用。诸如免疫检查点抑制剂和细胞治疗等免疫疗法正在彻底改变癌症治疗方法。然而,尽管在一些患者中有显着效果,但多数患者对免疫疗法没有反应。要将免疫疗法扩展到目前仍然难以治愈的常见癌症,仍有许多工作要做。

Methods Mol Biol:利用CRISPR / Cas9构建视网膜变性模型

加拿大哥伦比亚大学眼科学与视觉科学系的Feehan JM等人近日在Methods Mol Biol杂志上发表了一篇文章,他们利用CRISPR / Cas9基因编辑技术构建了视网膜变性的动物模型。

CTX001获得FDA快速通道资格用于治疗镰状细胞病

CRISPR治疗公司和Vertex制药公司近日宣布,美国食品和药品管理局(FDA)已授予CTX001快速通道资格用于治疗镰状细胞病(SCD)。CTX001是针对患有严重血红蛋白病患者的研究性、自体性、CRISPR基因编辑的造血干细胞疗法。

PLAST RECONSTR SURG:CRISPR基因组编辑有望用于整形外科中

CRISPR基因组编辑技术有望成为基因工程和治疗的“变革性飞跃”,它几乎影响到医学的每个领域。根据2018年11月发表在美国整形外科学会(American Society of Plastic Surgeon)官方期刊Plastic and Reconstructive Surgery上的一篇标题为“CRISPR Craft: DNA Editing the Reconstructive Ladd